Literature DB >> 19336749

Therapy-related myeloid neoplasms.

Richard A Larson1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19336749      PMCID： PMC2663607          DOI： 10.3324/haematol.2008.005157

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  22 in total

1.  Autologous stem cell transplantation for therapy-related acute myeloid leukemia and myelodysplastic syndrome.

Authors:  N Kröger; R Brand; A van Biezen; J-Y Cahn; S Slavin; D Blaise; J Sierra; A Zander; D Niederwieser; T de Witte
Journal:  Bone Marrow Transplant       Date:  2006-01       Impact factor: 5.483

2.  Prevalence of the inactivating 609C-->T polymorphism in the NAD(P)H:quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia.

Authors:  R A Larson; Y Wang; M Banerjee; J Wiemels; C Hartford; M M Le Beau; M T Smith
Journal:  Blood       Date:  1999-07-15       Impact factor: 22.113

Review 3.  Alternative genetic pathways and cooperating genetic abnormalities in the pathogenesis of therapy-related myelodysplasia and acute myeloid leukemia.

Authors:  J Pedersen-Bjergaard; D H Christiansen; F Desta; M K Andersen
Journal:  Leukemia       Date:  2006-09-21       Impact factor: 11.528

Review 4.  The molecular basis of leukemia.

Authors:  D Gary Gilliland; Craig T Jordan; Carolyn A Felix
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2004

5.  Allogeneic bone marrow transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia: a long-term study of 70 patients-report of the French society of bone marrow transplantation.

Authors:  I Yakoub-Agha; P de La Salmonière; P Ribaud; L Sutton; E Wattel; M Kuentz; J P Jouet; G Marit; N Milpied; E Deconinck; N Gratecos; M Leporrier; I Chabbert; D Caillot; G Damaj; C Dauriac; F Dreyfus; S François; L Molina; M L Tanguy; S Chevret; E Gluckman
Journal:  J Clin Oncol       Date:  2000-03       Impact factor: 44.544

Review 6.  Stem cell transplantation for secondary acute myeloid leukemia: evaluation of transplantation as initial therapy or following induction chemotherapy.

Authors:  J E Anderson; T A Gooley; G Schoch; C Anasetti; W I Bensinger; R A Clift; J A Hansen; J E Sanders; R Storb; F R Appelbaum
Journal:  Blood       Date:  1997-04-01       Impact factor: 22.113

Review 7.  Treatment of therapy-related leukemia and myelodysplastic syndrome.

Authors:  H M Kantarjian; E H Estey; M J Keating
Journal:  Hematol Oncol Clin North Am       Date:  1993-02       Impact factor: 3.722

8.  Risk factors for therapy-related myelodysplastic syndrome and acute myeloid leukemia treated with allogeneic stem cell transplantation.

Authors:  Nicolaus Kröger; Ronald Brand; Anja van Biezen; Axel Zander; Judith Dierlamm; Dietger Niederwieser; Agnès Devergie; Tapani Ruutu; Jackie Cornish; Per Ljungman; Alois Gratwohl; Catherine Cordonnier; Dietrich Beelen; Eric Deconinck; Argiris Symeonidis; Theo de Witte
Journal:  Haematologica       Date:  2009-03-10       Impact factor: 9.941

9.  Short remission durations in therapy-related leukemia despite cytogenetic complete responses to high-dose cytarabine.

Authors:  R A Larson; M Wernli; M M Le Beau; K M Daly; L H Pape; J D Rowley; J W Vardiman
Journal:  Blood       Date:  1988-10       Impact factor: 22.113

10.  Haploinsufficiency of EGR1, a candidate gene in the del(5q), leads to the development of myeloid disorders.

Authors:  John M Joslin; Anthony A Fernald; Thelma R Tennant; Elizabeth M Davis; Scott C Kogan; John Anastasi; John D Crispino; Michelle M Le Beau
Journal:  Blood       Date:  2007-04-09       Impact factor: 22.113
View more
  21 in total

1.  Successful treatment with low-dose imatinib mesylate of therapy-related myeloid neoplasm harboring TEL-PDGFRB in a patient with acute promyelocytic leukemia.

Authors:  Norio Asou; Eisaku Iwanaga; Tomoko Nanri; Hiroaki Mitsuya
Journal:  Haematologica       Date:  2010-09       Impact factor: 9.941

2.  Myeloid neoplasms after breast cancer: "therapy-related" not an independent poor prognostic factor.

Authors:  Yiming Chen; Zeev Estrov; Sherry Pierce; Wei Qiao; Gautam Borthakur; Farhad Ravandi; Tapan Kadia; Mark Brandt; Susan O'Brien; Elias Jabbour; Guillermo Garcia-Manero; Jorge Cortes; Miloslav Beran
Journal:  Leuk Lymphoma       Date:  2014-08-13

3.  Unexpected Second Primary Malignancies Detected by F-18 FDG PET/CT During Follow-up for Primary Malignancy: Two Case Reports.

Authors:  Ji-In Bang; Eun Seong Lee; Tae-Sung Kim; Seok-Ki Kim
Journal:  Nucl Med Mol Imaging       Date:  2014-10-30

4.  Effect of therapy-related acute myeloid leukemia on the outcome of patients with acute myeloid leukemia.

Authors:  Ana Espírito ESPíRITO Santo; Sérgio Chacim; Isabel Ferreira; Luís Leite; Claudia Moreira; Dulcineia Pereira; Margarida Dantas Dantas Brito; Marta Nunes; Nelson Domingues; Isabel Oliveira; Ilídia Moreira; Angelo Martins; Luísa Viterbo; José Mário Mariz; Rui Medeiros
Journal:  Oncol Lett       Date:  2016-05-17       Impact factor: 2.967

5.  Validation of the revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes.

Authors:  Asmita Mishra; Maria Corrales-Yepez; Najla Al Ali; Mohamed Kharfan-Dabaja; Eric Padron; Ling Zhang; Pearlie K Epling-Burnette; Javier Pinilla-Ibarz; Jeffrey E Lancet; Alan F List; Rami S Komrokji
Journal:  Am J Hematol       Date:  2013-05-30       Impact factor: 10.047

6.  Therapy-related myeloid neoplasm after peptide receptor radionuclide therapy (PRRT) in 1631 patients from our 20 years of experiences: prognostic parameters and overall survival.

Authors:  M Chantadisai; H R Kulkarni; R P Baum
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-11-27       Impact factor: 9.236

7.  Therapy-related myeloid malignancies in myeloma.

Authors:  X Papanikolaou; B Barlogie; S Z Usmani
Journal:  Mediterr J Hematol Infect Dis       Date:  2011-10-24       Impact factor: 2.576

8.  Risk factors for de novo and therapy-related myelodysplastic syndromes (MDS).

Authors:  Rina Yarosh; Michelle A Roesler; Thomas Murray; Adina Cioc; Betsy Hirsch; Phuong Nguyen; Erica Warlick; Jenny N Poynter
Journal:  Cancer Causes Control       Date:  2021-01-04       Impact factor: 2.506

9.  Karyotypic and fluorescent in situ hybridization study of the centromere of chromosome 7 in secondary myeloid neoplasms.

Authors:  Roberta Sandra da Silva Tanizawa; Cristina Aiko Kumeda; Raymundo Soares de Azevedo Neto; Aline de Medeiros Leal; Patrícia de Barros Ferreira; Elvira Deolinda Rodrigues Pereira Velloso
Journal:  Rev Bras Hematol Hemoter       Date:  2011

10.  Therapy-related myeloid neoplasms in 39 Korean patients: a single institution experience.

Authors:  Hee Jae Huh; Soo Hyun Lee; Keon Hee Yoo; Ki Woong Sung; Hong Hoe Koo; Kihyun Kim; Jun-Ho Jang; Chulwon Jung; Sun-Hee Kim; Hee-Jin Kim
Journal:  Ann Lab Med       Date:  2013-02-21       Impact factor: 3.464
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.